Shionogi & Co., Ltd. (TYO: 4507)

Market Cap	1.86T
Revenue (ttm)	423.36B
Net Income (ttm)	150.11B
Shares Out	283.49M
EPS (ttm)	522.09
PE Ratio	12.57
Forward PE	11.29
Dividend	170.00 (2.60%)
Ex-Dividend Date	Sep 27, 2024

Volume	667,200
Open	6,468.00
Previous Close	6,548.00
Day's Range	6,454.00 - 6,565.00
52-Week Range	5,834.00 - 8,137.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 28, 2024

About Shionogi &

Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug. It also develops S-872600 an influenza nasal vaccine; S-875670 anCOVID-19 nasal vaccine; S-540956...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1878
• Employees: 4,959
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4507

Financial Performance

In 2023, Shionogi &'s revenue was 435.08 billion, an increase of 1.97% compared to the previous year's 426.68 billion. Earnings were 162.03 billion, a decrease of -12.40%.